Latus Bio
Latus Bio is a clinical-stage biotech developing AAV-based gene therapies for CNS disorders using proprietary engineered capsids (AAV-DB-3, AAV-Ep+) and AI/ML-driven discovery, with lead programs in Huntington's disease and CLN2 Batten disease.
- Company typePrivate
- Founded2024
- HeadquartersPhiladelphia, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Latus Bio does
Latus Bio is a clinical-stage biotechnology company developing AAV-based gene therapies for central nervous system (CNS) and peripheral diseases, founded in 2024 and headquartered in Philadelphia with operations in Boston. The company's core offering is a proprietary AAV discovery and engineering platform that combines unbiased non-human primate screening with AI/ML-driven design, built on a dataset of over 100 million unique route-capsid-tissue-cell type combinations from nine in vivo NHP campaigns. Two lead engineered capsid variants — AAV-DB-3 (for deep brain delivery to the striatum) and AAV-Ep+ (for broad CNS distribution via CSF protein secretion) — power the lead programs and have demonstrated 100x+ greater potency than traditional AAV5 vectors in preclinical primate studies, with claimed dose requirements 1/100 to 1/10,000 of competitors and cost of goods less than 1/10 of competing approaches.
The company's clinical pipeline is concentrated in two ultra-rare CNS programs: LTS-201, an AAV-DB-3-based gene therapy targeting the MSH3 gene for Huntington's disease (IND submission planned Q3 2026), and LTS-101, an AAV-Ep+-based gene therapy delivering functional TPP1 for CLN2 (Batten) disease (FDA IND cleared in December 2025 with Orphan Drug, Rare Pediatric Disease, and Fast Track designations). The platform is licensed from Children's Hospital of Philadelphia, and the company plans to expand into broader CNS indications (Parkinson's, lysosomal storage disorders) and peripheral tissues (liver, muscle, kidney, heart, eye, ear), as well as pursue strategic partnerships to license capsid technology to other gene therapy developers.
As a pre-revenue clinical-stage biotech, Latus Bio is funded entirely by equity capital, having raised $97 million in total Series A financing ($54M initial close in May 2024 led by 8VC and DCVC Bio, plus a $43M extension in May 2026). The company plans to commercialize gene therapies through specialty treatment centers and hospital pharmacies upon potential FDA approval, with revenue expected from one-time high-price product sales and potential platform licensing/royalties. Leadership includes CEO P. Peter Ghoroghchian, founder and SAB Chair Beverly Davidson (a leading gene therapy expert from CHOP and 2026 ASGCT Outstanding Achievement Award recipient), CSMO Jang-Ho Cha, CDO John Connelly, CBO Bethany Mancilla, and COO Ainslie Little.
Latus Bio firmographics
Firmographics- Name
- Latus Bio
- Legal name
- Latus Bio, Inc.
- Website
- https://latusbio.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Latus Bio is a clinical-stage biotech developing AAV-based gene therapies for CNS disorders using proprietary engineered capsids (AAV-DB-3, AAV-Ep+) and AI/ML-driven discovery, with lead programs in Huntington's disease and CLN2 Batten disease.
- Ownership category
- akta.pro rank
Latus Bio industry classification
Industry- Product category
- Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Neurology/CNS Gene Therapies (HLAAACAH)
- akta.pro secondary industries
- AAV Vector Gene Therapy Developers (HLAAACAA), Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
Keywords
Where Latus Bio is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Latus Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Gene Therapy Product Sales: Pre-revenue clinical-stage biotech. Revenue will be generated through commercialization of proprietary gene therapy candidates (LTS-201, LTS-101) upon FDA approval. Gene therapies are typically high-price, one-time or durable treatments with potential for premium reimbursement.
- Platform Licensing / Strategic Partnerships: Company has indicated plans to pursue strategic partnerships to expand its AAV capsid platform beyond its own pipeline, potentially licensing proprietary capsid technology to other gene therapy developers for additional indications.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Latus Bio product offering
Product offeringCore offering
Latus Bio is a clinical-stage biotechnology company developing AAV-based gene therapy candidates for central nervous system (CNS) disorders. Its lead programs are LTS-201 for Huntington's disease and LTS-101 for CLN2 (Batten) disease, both built on proprietary engineered AAV capsid variants (AAV-DB-3 and AAV-Ep+) discovered through unbiased NHP screening and AI/ML-driven design to enable low-dose, targeted gene delivery to deep brain regions.
Product overview
Latus Bio is a biotechnology company developing AAV gene therapies for central nervous system (CNS) and peripheral diseases. The company's core offering is its AAV discovery and engineering platform, which combines proprietary engineered AAV capsid variants with optimized routes of administration to enable low-dose, cell-specific gene therapy delivery. The platform supports two lead clinical-stage product candidates: LTS-101 (using the AAV-Ep+ capsid) for CLN2 disease, and LTS-201 (using the AAV.DB-3 capsid) for Huntington's disease. The company's approach leverages AI/ML-driven capsid and payload engineering to improve targeting precision, reduce dosage requirements, and address scalability limitations that have traditionally confined gene therapy to ultra-rare diseases.
Differentiator
Problem solved
Functional benefit
Brands
- LTS-101: Gene therapy candidate for CLN2 disease using AAV-Ep+ capsid to deliver TPP1 throughout the CNS.
- LTS-201
- AAV.DB-3
- AAV-Ep+
Products and services
- LTS-101 Gene therapy candidate exploiting the AAV-Ep+ capsid to deliver functional TPP1 throughout the CNS for treatment of CLN2 disease, a fatal ultra-rare neurodegenerative lysosomal storage disorder.
- LTS-201 Gene therapy candidate using the AAV-DB-3 capsid targeting the MSH3 gene to inhibit somatic CAG repeat expansion in Huntington's disease, intended to delay or halt disease progression.
- AAV Capsid Discovery and Engineering Platform Integrated AAV discovery platform combining AI/ML computational methods with unbiased NHP screens to identify novel AAV capsid variants matched to optimized routes of administration; supports potential licensing to other gene therapy developers.
Quantifiable outcome
- 100x or greater potency vs. traditional AAV5 vectors in non-human primate studies for deep brain regions
- +4 more outcomes
Companies that use Latus Bio
Customer profileSegments3 records
Ideal customer profiles3 records
Latus Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature3 records
Latus Bio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- Dr. Pranam Chatterjee (University of Pennsylvania)minorAdded to Scientific Advisory Board as an expert in peptide and protein modeling to support Latus Bio's AI/ML-driven capsid and payload engineering strategy.
- Dr. Philip Kim (University of Toronto)minorAdded to Scientific Advisory Board as an expert in peptide and protein modeling to advance Latus Bio's three AI/ML focus areas: AAV capsid engineering, payload engineering, and bespoke therapeutic tailoring.
- Children's Hospital of Philadelphia (CHOP)coreLatus Bio was co-founded based on proprietary capsid technology licensed from CHOP. This is the foundational technology relationship underlying the company's entire platform. Beverly Davidson, Ph.D., formerly of CHOP, is the company's founder and SAB Chair.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Latus Bio competitors and assessment
Company assessmentEmerging players
- StrideBio: Engineered AAV capsid development company with structural and computational design capabilities, directly comparable to Latus's capsid engineering platform focus.
- Capsida Biotherapeutics: Gene therapy company developing engineered AAV capsids with AI/ML-driven discovery for CNS and other tissues, directly comparable to Latus's capsid engineering platform and AI/ML discovery approach.
- Affinia Therapeutics: Gene therapy company with engineered AAV capsid platform targeting CNS and other tissues, directly comparable to Latus's approach of capsid engineering for tissue-specific delivery in CNS disorders.
Direct peers
- Lexeo Therapeutics: Clinical-stage gene therapy company with CNS and cardiac programs leveraging AAV delivery, comparable as a similarly staged competitor in CNS-targeted AAV gene therapy development.
- Taysha Gene Therapies: Clinical-stage CNS gene therapy company with multiple AAV-based programs for rare neurological diseases, comparable in pipeline focus, stage, and platform approach to Latus.
- Voyager Therapeutics: Clinical-stage AAV gene therapy company focused on CNS diseases including Huntington's and ALS, with proprietary capsid engineering efforts — overlapping directly with Latus's capsid platform and CNS pipeline strategy.
- Krystal Biotech: Commercial-stage gene therapy company focused on rare diseases with a non-replicating viral vector platform, providing a comparable business model reference for ultra-rare disease gene therapy commercialization.
- UniQure: Clinical-stage gene therapy company developing AMT-130 for Huntington's disease using AAV delivery to the CNS — a direct competitor to Latus's LTS-201 program with a similar indication and approach.
Broad incumbents
- Regenxbio: Established AAV gene therapy platform company with multiple clinical and commercial programs, serving as both a potential licensor/licensing partner and a competitor with deeper manufacturing and clinical capabilities.
- Spark Therapeutics (Roche): Established gene therapy company (now part of Roche) with commercial gene therapy products, providing a comparable reference for AAV-based therapeutic development and a potential strategic acquirer/licensing partner.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Latus Bio social profiles
Digital presenceLatus Bio compliance and trust
Trust signalCompliance4 records
Latus Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Latus Bio leadership team
Management profileNumber of profiles
Profiles12 records
Latus Bio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Latus Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Latus Bio
What does Latus Bio do?
Latus Bio is a clinical-stage biotechnology company developing AAV-based gene therapy candidates for central nervous system (CNS) disorders. Its lead programs are LTS-201 for Huntington's disease and LTS-101 for CLN2 (Batten) disease, both built on proprietary engineered AAV capsid variants (AAV-DB-3 and AAV-Ep+) discovered through unbiased NHP screening and AI/ML-driven design to enable low-dose, targeted gene delivery to deep brain regions.
Is Latus Bio a public or private company?
Latus Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Latus Bio founded?
Latus Bio was founded in 2024. It employs 11 to 50 people.
Where is Latus Bio based?
Latus Bio is headquartered in Philadelphia, United States, in the North America region.
How does Latus Bio make money?
Two revenue lines are on record. Gene Therapy Product Sales are the primary driver. The others are platform Licensing / Strategic Partnerships.
Who are Latus Bio's main competitors?
Emerging players on record are StrideBio, Capsida Biotherapeutics and Affinia Therapeutics. Direct peers are Lexeo Therapeutics, Taysha Gene Therapies, Voyager Therapeutics, Krystal Biotech and UniQure. Broad incumbents are Regenxbio and Spark Therapeutics (Roche).
Does Latus Bio have an API?
No public API is recorded for Latus Bio.
What industry is Latus Bio in?
Latus Bio's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2836.